SK invests $350 million in U.S. Center for Breakthrough Medicines
SK Inc. invested $350 million in the Center for Breakthrough Medicines (CBM), becoming the second largest shareholder of the Philadelphia-based contract and development manufacturing organization (CDMO) specializing in gene and cell therapy.